Cargando…
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the front-line therapy. In this phase 2 trial, 2...
Autores principales: | Shi, Tingyan, Jiang, Rong, Pu, Hong, Yang, Huijuan, Tu, Dongsheng, Dai, Zhiyuan, Cai, Yunlang, Zhang, Yuqin, Cheng, Xi, Jia, Huixun, Tu, Ruiqin, Wang, Huaying, Tang, Jie, Luan, Yuting, Cai, Shumo, Zang, Rongyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738091/ https://www.ncbi.nlm.nih.gov/pubmed/31383985 http://dx.doi.org/10.1038/s41416-019-0543-1 |
Ejemplares similares
-
Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial
por: Shi, Tingyan, et al.
Publicado: (2018) -
The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery
por: Cheng, Xi, et al.
Publicado: (2004) -
A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer
por: Hasegawa, Kosei, et al.
Publicado: (2020) -
Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2022) -
Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
por: Zang, Rongyu, et al.
Publicado: (2019)